2024 - Postbiotics: Novel Solutions for Digestive Health
Date2024-06-04
Deadline2024-06-04
VenueONLINE-VIRTUAL, USA - United States
KeywordsLife Sciences; Clinical Trials; Food
Topics/Call fo Papers
Attend an informative webinar discussing the link between digestive health and pro-/post-biotics using data from first human clinical data on patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Increasingly, pre-clinical and clinical research supports the importance of gut health in a wide variety of physiological systems, ranging from digestive health and immune function support to cardiovascular and mental health. With nearly 80 percent of consumers recognizing the link between digestive health and overall well-being, it is not surprising this category is the largest amongst biotic products.
ADM’s most recent clinical study uses the dual probiotic and postbiotic Bifidobacterium longum ES1 in a population of adults with diarrhea-predominant IBS-D. In this webinar, the speaker will walk through the main findings from this study and the science around digestive health and postbiotics.
By attending this webinar, the attendees will gain insights into the following:
Latest clinical trial data from a large multi-centre randomized controlled trial
Explore the use of postbiotics for digestive health
First human clinical data for a dual pro- and post-biotic
Register for this webinar today to explore invaluable insights from a large multi-center randomized controlled trial and first human clinical data for a novel dual pro- and postbiotic for diarrhea-predominant IBS-D.
Keywords: Clinical Trials, Clinical Research, Clinical Data, Marketing, Probiotics, Nutraceuticals, Gut Health, IBS, Gut Microbiome
Increasingly, pre-clinical and clinical research supports the importance of gut health in a wide variety of physiological systems, ranging from digestive health and immune function support to cardiovascular and mental health. With nearly 80 percent of consumers recognizing the link between digestive health and overall well-being, it is not surprising this category is the largest amongst biotic products.
ADM’s most recent clinical study uses the dual probiotic and postbiotic Bifidobacterium longum ES1 in a population of adults with diarrhea-predominant IBS-D. In this webinar, the speaker will walk through the main findings from this study and the science around digestive health and postbiotics.
By attending this webinar, the attendees will gain insights into the following:
Latest clinical trial data from a large multi-centre randomized controlled trial
Explore the use of postbiotics for digestive health
First human clinical data for a dual pro- and post-biotic
Register for this webinar today to explore invaluable insights from a large multi-center randomized controlled trial and first human clinical data for a novel dual pro- and postbiotic for diarrhea-predominant IBS-D.
Keywords: Clinical Trials, Clinical Research, Clinical Data, Marketing, Probiotics, Nutraceuticals, Gut Health, IBS, Gut Microbiome
Other CFPs
- A Pathway to Better Health: How Supply Chains Deliver on the Promise of GLP-1 Drugs
- Leveraging Active Diagnostic Stewardship Interventions to Optimize the Outcomes of Patients with Bacteremia
- Optimizing eCOA and IRT – Empowering the Modern Clinical Trial
- Accelerating Clinical Translation of Antibody-Drug Conjugates with Hybrid AI
- Generative AI in Life Sciences Industry: Ethics, Applications and Transformations
Last modified: 2024-05-16 02:49:57